Get our newsletter delivered directly to your inbox
I have already subscribed | Do not show this message again
Your email has been successfully registered.
The first phase of the vaccine took place in the U.S. and Belgium, where a large study proved the drug does not produce adverse reactions.
Spain's Health Minister Salvador Illa Friday announced that his country will take part in the first clinical trial of the COVID-19 vaccine developed by Belgian Janssen Pharmaceuticals, which is a property of the U.S. company Johnson & Johnson.
This will be the second phase of the vaccine's experiments which will have the participation of 190 healthy volunteers. Germany and Belgium will also host this new phase of the process.
"The volunteers will be healthy people between 18 and 65 years old. The experiment also will include healthy people over 65," Illa informed, adding that the selection process will take place next week.
"The experiment will let us see if the vaccine confers protection," researcher Vicente Larraga said and explained that phase two normally lasts one year, "but the trial is progressing quickly, and the process could last only a few months."
Scientists from Mexico, the United States, Spain, and Italy are developing a technological algorithm to identify #COVID19 patients just by listening to their cough from their cell phones.https://t.co/OfDMUBhhLV